DDInter1881 DDInter1607
Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone].
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulations and as capsules. While ritonavir is not an active antiviral agent against hepatitis C virus (HCV) infection, it is added in combination therapies indicated for the treatment of HCV infections as a booster. Ritonavir is a potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of other protease inhibitors such as and overall drug exposure. American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as first-line therapy for HCV Genotype 1a/b and 4 treatment-naïve patients with or without cirrhosis. Ritonavir is found in a fixed-dose combination product with , , and as the FDA-approved product Viekira Pak. First approved in December 2014, Viekira Pak is indicated for the treatment of HCV genotype 1b without cirrhosis or with compensated cirrhosis, and when combined with Ribavirin for the treatment of HCV genotype 1a without cirrhosis or with compensated cirrhosis. Ritonavir is also available as a fixed-dose combination product with and as the FDA- and Health Canada-approved product Technivie. First approved in July 2015, Technivie is indicated in combination with Ribavirin for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis. In Canada, ritonavir is also available as a fixed-dose combination product with , , and as the Health Canada-approved, commercially available product Holkira Pak. First approved in January 2015, Holkira Pak is indicated for the treatment of HCV genotype 1b with or without cirrhosis, and when combined with Ribavirin for the treatment of HCV genotype 1a with or without cirrhosis. The inclusion of ritonavir can select for HIV-1 protease inhibitor resistance-associated substitutions. Any HCV/HIV-1 co-infected patients treated with ritonavir-containing combination therapies should also be on a suppressive antiretroviral drug regimen to reduce the risk of HIV-1 protease inhibitor drug resistance. Ritonavir is combined with other drugs to treat coronavirus disease 2019 (COVID-19) in patients at risk for progressing into a severe form of the disease, such as [nirmatrelvir].
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Atazanavir
Atazanavir {u} (Compound) resembles {v} (Compound) Ritonavir
Troglitazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zaleplon
Zaleplon {u} (Compound) binds {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) is bound by {v} (Compound) Ritonavir
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Atazanavir
Atazanavir {u} (Compound) resembles {v} (Compound) Lopinavir
Lopinavir {u} (Compound) resembles {v} (Compound) Ritonavir
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Atazanavir
Atazanavir {u} (Compound) binds {v} (Gene) ABCC1
ABCC1 {u} (Gene) is bound by {v} (Compound) Ritonavir
Troglitazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dolutegravir
Dolutegravir {u} (Compound) causes {v} (Side Effect) Insomnia
Insomnia {u} (Side Effect) is caused by {v} (Compound) Ritonavir
Troglitazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Lidocaine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Atazanavir
Atazanavir {u} (Compound) resembles {v} (Compound) Ritonavir
Troglitazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mirabegron
Mirabegron {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2D6 Inhibitors
Cytochrome P450 2D6 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Ritonavir
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Atazanavir
Atazanavir {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inhibitors
Cytochrome P450 3A4 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Ritonavir
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Atazanavir
Atazanavir {u} (Compound) causes {v} (Side Effect) Blood triglycerides increased
Blood triglycerides increased {u} (Side Effect) is caused by {v} (Compound) Ritonavir
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin glargine
Insulin glargine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Atazanavir
Atazanavir {u} (Compound) resembles {v} (Compound) Ritonavir
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir and Atazanavir (Compound) resembles Ritonavir (Compound)
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Zaleplon and Zaleplon (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Ritonavir (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir and Atazanavir (Compound) resembles Lopinavir (Compound) and Lopinavir (Compound) resembles Ritonavir (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir and Atazanavir (Compound) binds ABCC1 (Gene) and ABCC1 (Gene) is bound by Ritonavir (Compound)
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Dolutegravir and Dolutegravir (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Ritonavir (Compound)
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir and Atazanavir (Compound) resembles Ritonavir (Compound)
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron (Compound) is included by Cytochrome P450 2D6 Inhibitors (Pharmacologic Class) and Cytochrome P450 2D6 Inhibitors (Pharmacologic Class) includes Ritonavir (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir and Atazanavir (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) and Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) includes Ritonavir (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir and Atazanavir (Compound) causes Blood triglycerides increased (Side Effect) and Blood triglycerides increased (Side Effect) is caused by Ritonavir (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir and Atazanavir (Compound) resembles Ritonavir (Compound)